Metro (MRU) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
4 Mar, 2026Executive summary
Q3 sales reached $6.871 billion, up 3.3% year-over-year, with food same-store sales up 1.9% and pharmacy same-store sales up 5.5%.
EBITDA grew 5.7% to $656 million, and adjusted EPS increased 12.6% to $1.52; fully diluted EPS rose 13.0% to $1.48.
Gross margin improved to 19.8% from 19.6% last year, driven by productivity gains and shrink improvement.
Online sales rose 14.4%, supported by expanded delivery partnerships and Click and Collect services.
Five new food stores were opened, supporting discount banner expansion.
Financial highlights
Adjusted net earnings were $332 million, up 8.8% year-over-year; net earnings reached $323 million, up 9.0%.
Operating expenses were $702 million, or 10.2% of sales, consistent with last year.
Net financial costs decreased to $45.3 million from $46.6 million, mainly due to lower interest expense.
Capital expenditures totaled $146 million, down $41 million, reflecting completion of automated distribution centers.
Effective tax rate dropped to 24.1% from 25.9%, aided by a provincial tax holiday.
Outlook and guidance
Continued focus on discount banner expansion, with 14 new stores planned for fiscal 2025.
Management expects modest SG&A leverage in coming quarters as duplicate costs have been lapped.
Sustained investments in retail networks and supply chain are expected to drive long-term growth.
Focus shifts to realizing efficiency gains after major supply chain investments.
Efforts to deliver value through merchandising, private label, and loyalty programs continue amid economic uncertainty.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, net earnings up 17.6%, supply chain investments ongoing.MRU
Q2 20254 Mar 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Sales up 3.5%, stable margins, but net earnings fell 14.6% amid automation costs.MRU
Q3 20244 Mar 2026 - Q4 saw higher margins, strong pharmacy and online sales growth, and a completed supply chain overhaul.MRU
Q4 20244 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026 - Strong results, board re-elections, and strategic growth plans highlighted, with rising dividends.MRU
AGM 20259 Jan 2026